Why the study?
Evidence was limited regarding the effectiveness and safety of combining PCC with idarucizumab in cases of multiple anticoagulant intoxication.
Does the combined use of fibrinogen concentrate, PCC, and idarucizumab reverse coagulopathy in a patient with dabigatran and apixaban intoxication?
Does the combined use of fibrinogen concentrate, PCC, and idarucizumab reverse coagulopathy in a patient with dabigatran and apixaban intoxication?
Combination therapy with fibrinogen concentrate, PCC, and idarucizumab may be effective and safe for reversing coagulopathy in cases of multiple direct oral anticoagulant intoxication.
May support multimodal reversal in mixed NOAC overdose; leaves open need for prospective validation.
This case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced coagulopathy. An 86-year-old patient, receiving apixaban therapy, presented to the Emergency Department after intentionally ingesting 50 tablets of dabigatran. The combination therapy contributed to the rapid normalization of coagulation parameters and stabilization of the patient's clinical status without subsequent thromboembolic complications. This case adds to the limited evidence on the effectiveness and safety of combining PCC with idarucizumab in cases of multiple anticoagulant intoxication.
No takes yet. Share an insight, caveat, or question.
Morando et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: